LRRK2 and Parkinson disease: Mdivi-1 may be more efficacious for PD patients with LRRK2 mutations or increased LRRK2 kinase activity, as LRRK2 binds to Drp1 to promote mitochondrial fission, and this effect is exacerbated with the LRRK2 G2019S mutat ion [144–146].